Ivermectin Nasal Spray for COVID19 Patients
Ivermectin Inhalation Forms in the Management of COVID-19 Egyptian Patients
1 other identifier
interventional
60
0 countries
N/A
Brief Summary
The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2 covid19
Started Sep 2020
Shorter than P25 for phase_2 covid19
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 10, 2020
CompletedFirst Posted
Study publicly available on registry
August 12, 2020
CompletedStudy Start
First participant enrolled
September 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedAugust 12, 2020
August 1, 2020
1 month
August 10, 2020
August 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PCR of SARS-Cov2 RNA
Negative PCR result of SARS-Cov2 RNA in COVID19 patients
14 days
Study Arms (3)
Ivermectin nasal spray
EXPERIMENTALIvermectin administered as nasal spray (one ml in each nostril two times daily)
Ivermectin oral
EXPERIMENTALIvermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.
standard care
EXPERIMENTALCOVID-19 cases will receive standard of care \[oxygen via masks or ventilators\]
Interventions
Ivermectin nasal spray one ml in each nostril two times daily
Ivermectin oral (one tablet 6 mg three times daily)
Eligibility Criteria
You may qualify if:
- mild to moderate severity who are confirmed to be positive for SARS COV 2.
You may not qualify if:
- patients with severe form of COVID-19 or those who are on ventilatory support or those with cytokine storm
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tanta Universitylead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kamal Okasha, PhD
Tanta Univesity faculty of Medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Vice President
Study Record Dates
First Submitted
August 10, 2020
First Posted
August 12, 2020
Study Start
September 1, 2020
Primary Completion
October 1, 2020
Study Completion
December 1, 2020
Last Updated
August 12, 2020
Record last verified: 2020-08
Data Sharing
- IPD Sharing
- Will not share